The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

FierceBiotech Names Obesity Company Gelesis to 'Fierce 15' List of Top Emerging Biotech Companies

September 15, 2010 5:32 am | by Bio-Medicine.Org | News | Comments

BOSTON, Sept. 15 /- Gelesis, a Boston-based obesity company, announced today that it has been named to the FierceBiotech "Fierce 15" list, designating it as one of the top emerging biotech companies of 2010. The editors evaluated hundreds of privately-held firms based on company vision,...


Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan

September 15, 2010 5:31 am | by Bio-Medicine.Org | News | Comments

IRVINE, Calif., Sept. 15 /- Masimo (Nasdaq: MASI ) announced today the Japanese Ministry of Health, Labor and Welfare (MHLW) regulatory clearance of its noninvasive and continuous hemoglobin (SpHb) measurement, available as part of the Masimo rainbow SET® platform.  Representing...


On-Demand RFID Label Printer Is in Color

September 15, 2010 5:29 am | Product Releases | Comments

Primera Technology Inc., a leading manufacturer of CD/DVD and Blu-ray DiscTM Publishers, offers its RX900 Color RFID Printer. RX900 is the world’s first and only full-color RFID “on demand” label printer, according to the company.


Restructured MDS holds steady on revenue, posts US$15 million loss

September 15, 2010 3:45 am | by The Associated Press | News | Comments

MDS Inc. (TSX:MDS) met analyst expectations for revenue at US$53 million in its fiscal third quarter but the restructured Canadian life sciences company reported a loss rather than a profit. The nuclear medicine imaging company's continuing operations lost US$15 million or 27 cents per share.

Leisureworld Announces September Dividend

September 15, 2010 3:45 am | by The Associated Press | News | Comments

Leisureworld Senior Care Corporation (TSX: LW) today announced that the Company's dividend for September, 2010 will be $0.0708 per share, representing $0.85 per share on an annualized basis. Payment will be made on October 15, 2010 to shareholders of record September 30, 2010.About...

OrthoAccel Technologies Committed to Plans for Positioning the United Kingdom as a Key Strategic Market for New Orthodontic Technology

September 15, 2010 3:32 am | by Bio-Medicine.Org | News | Comments

HOUSTON, Sept. 15 /- OrthoAccel Technologies, Inc. has announced commercial plans for the United Kingdom that entail considerable business activity and economic impact.  Last year, the Company hired a Director of Sales based in Wales.  Recently, a full-market UK release of the...


U.S. Food and Drug Administration Extends Review Timeline for BRILINTA (Ticagrelor) New Drug Application

September 15, 2010 2:32 am | by Bio-Medicine.Org | News | Comments

WILMINGTON, Del., Sept. 15 /- AstraZeneca (NYSE: AZN ) today announced that the U.S. Food and Drug Administration (FDA) has extended the time to complete its review of the New Drug Application (NDA) for ticagrelor (BRILINTA). (Logo:


Compandia Announces Name Change and New Diagnostic Concept

September 14, 2010 11:33 pm | by Bio-Medicine.Org | News | Comments

Compandia Announces Name Change and New Diagnostic Concept -- NOTTINGHAM, England, September 15, 2010 /-


Study: Mental illness stigma entrenched in American culture; new strategies needed

September 14, 2010 9:37 pm | by EurekAlert | News | Comments

(Indiana University) A joint study by Indiana University and Columbia University researchers found no change in prejudice and discrimination toward people with serious mental illness or substance abuse problems despite a greater embrace by the public of neurobiological explanations...


Urgent need for prostate cancer screening amongst Dutch men

September 14, 2010 9:37 pm | by EurekAlert | News | Comments

(European Association of Urology) A recent TNS NIPO survey, on behalf of the Dutch Association of Urology and the European Association of Urology, showed that almost four out of 10 Dutch men of 50 years and older suffer, or have suffered, from urinary complaints. The same number of...


Brandeis hosts Boston-Israel life sciences summit

September 14, 2010 9:37 pm | by Mass High Tech: The Journal of New England Technology | News | Comments

Brandeis International Business School is getting ready to welcome 15 Israeli life sciences companies to the school on October 18 and 19 as part of what organizers are calling a summit between Israeli and local companies seeking collaborations between the two clusters.

<i>The List: </i>New England's largest medical device manufacturers

September 14, 2010 9:37 pm | by Mass High Tech: The Journal of New England Technology | News | Comments

The medical device industry is change, as the manufacturers warily eyeball new financial and regulatory changes coming their way. Mass High Tech tallied the 28 largest medical device manufacturers in New England – take a look at their employment and sales numbers.

A Drug Shows Promise in Autism

September 14, 2010 9:35 pm | by Massachusetts Institute of Technology | News | Comments

A chemical that alters chemical signaling seems to ease anxiety and other symptoms.


Radiation exposure poses similar risk of first and second cancers in atomic bomb survivors

September 14, 2010 9:34 pm | by EurekAlert | News | Comments

(Fred Hutchinson Cancer Research Center) The first large-scale study of the relationship between radiation dose and risk of multiple cancers among atomic bomb survivors in Hiroshima and Nagasaki, Japan, reveals a similar risk in the development of first and second subsequent cancers.


Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder

September 14, 2010 5:36 pm | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Sept. 14 /- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.